Search - tctmd.com

Displaying 101 - 120 of 446

Sort: Relevancy | Date

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

News Conference News HRS 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

May 02, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Postmarketing Studies of CV Devices Still Lacking in the US

News Daily News

Postmarketing Studies of CV Devices Still Lacking in the US

March 17, 2022

The SWISS-APERO Trial

Podcast TCTMD Talking Points

The SWISS-APERO Trial

March 02, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Presentation TCT 2021

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Presenter: Roberto Galea

November 06, 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

November 06, 2021

Percutaneous Retrieval of a Malfunctioning WATCHMAN Device

Presentation TCT 2021

Percutaneous Retrieval of a Malfunctioning WATCHMAN Device

Presenter: Coty Jewell

November 05, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presentation TCT 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presenter: Dhanunjaya Lakkireddy

November 05, 2021

TCT 564: A New Perspective: Intracardiac Echocardiographic Guidance for the Implantation of a Left Atrial Appendage Occluder Device (Watchman) with a Leadless Pacemaker (Micra)

Presentation TCT 2021

TCT 564: A New Perspective: Intracardiac Echocardiographic Guidance for the Implantation of a Left Atrial Appendage Occluder Device (Watchman) with a Leadless Pacemaker (Micra)

Presenter: Kristen Brown

November 04, 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

News Opinion Editor's Corner TCT 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

November 01, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

FDA Investigating Possible Sex Differences in LAAO Outcomes

News Daily News

FDA Investigating Possible Sex Differences in LAAO Outcomes

September 27, 2021

Delayed Peridevice Leak Not Uncommon After Watchman Implant

News Daily News

Delayed Peridevice Leak Not Uncommon After Watchman Implant

September 03, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

FDA Approves Amplatzer Amulet LAA Occluder

News Daily News

FDA Approves Amplatzer Amulet LAA Occluder

August 17, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.